Effectiveness of varicella vaccine in children infected with HIV

Moeun Son; Eugene D. Shapiro; Philip Larussa; Natalie Neu; David E. Michalik; Michelle Meglin; Andrea Jurgrau; Wally Bitar; Marietta Vasquez; Patricia Flynn; Anne A. Gershon

doi:10.1086/652798

Effectiveness of varicella vaccine in children infected with HIV

Moeun Son, Eugene D. Shapiro, Philip Larussa, Natalie Neu, David E. Michalik, Michelle Meglin, Andrea Jurgrau, Wally Bitar, Marietta Vasquez, Patricia Flynn, Anne A. Gershon

Obstetrics and Gynecology

Research output: Contribution to journal › Article › peer-review

58 Scopus citations

Abstract

Although varicella vaccine is given to clinically stable human immunodeficiency virus (HIV)-infected children, its effectiveness is unknown. We assessed its effectiveness by reviewing the medical records of closely monitored HIV-infected children, including those receiving highly active antiretroviral therapy (HAART) between 1989 and 2007. Varicella immunization and development of varicella or herpes zoster were noted. Effectiveness was calculated by subtracting from 1 the rate ratios for the incidence rates of varicella or herpes zoster in vaccinated versus unvaccinated children. The effectiveness of the vaccine was 82% (95% confidence interval [CI], 24%-99%; P = .01) against varicella and was 100% (95% CI, 67%-100%; P<.001) against herpes zoster. When the analysis was controlled for receipt of HAART, vaccination remained highly protective against herpes zoster.

Original language	English (US)
Pages (from-to)	1806-1810
Number of pages	5
Journal	Journal of Infectious Diseases
Volume	201
Issue number	12
DOIs	https://doi.org/10.1086/652798
State	Published - Jun 15 2010

ASJC Scopus subject areas

Immunology and Allergy
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1086/652798

Cite this

@article{5341aaea1da043b392a23d592ce38c92,

title = "Effectiveness of varicella vaccine in children infected with HIV",

abstract = "Although varicella vaccine is given to clinically stable human immunodeficiency virus (HIV)-infected children, its effectiveness is unknown. We assessed its effectiveness by reviewing the medical records of closely monitored HIV-infected children, including those receiving highly active antiretroviral therapy (HAART) between 1989 and 2007. Varicella immunization and development of varicella or herpes zoster were noted. Effectiveness was calculated by subtracting from 1 the rate ratios for the incidence rates of varicella or herpes zoster in vaccinated versus unvaccinated children. The effectiveness of the vaccine was 82% (95% confidence interval [CI], 24%-99%; P = .01) against varicella and was 100% (95% CI, 67%-100%; P<.001) against herpes zoster. When the analysis was controlled for receipt of HAART, vaccination remained highly protective against herpes zoster.",

author = "Moeun Son and Shapiro, {Eugene D.} and Philip Larussa and Natalie Neu and Michalik, {David E.} and Michelle Meglin and Andrea Jurgrau and Wally Bitar and Marietta Vasquez and Patricia Flynn and Gershon, {Anne A.}",

note = "Funding Information: Financial support: National Institutes of Health (grant AI 24021 to A.A.G. and grant U01 AI 069470 to P.L.); American Lebanese Syrian Associated Charities (support to St. Jude Children{\textquoteright}s Research Hospital); National Center for Research Resources (Clinical and Translational Science Awards KL2 RR024138 and UL1 RR024139, grant K24 RR022477 [E.D.S.], and grant K23AI068280 to M.V.).",

year = "2010",

month = jun,

day = "15",

doi = "10.1086/652798",

language = "English (US)",

volume = "201",

pages = "1806--1810",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "12",

}

TY - JOUR

T1 - Effectiveness of varicella vaccine in children infected with HIV

AU - Son, Moeun

AU - Shapiro, Eugene D.

AU - Larussa, Philip

AU - Neu, Natalie

AU - Michalik, David E.

AU - Meglin, Michelle

AU - Jurgrau, Andrea

AU - Bitar, Wally

AU - Vasquez, Marietta

AU - Flynn, Patricia

AU - Gershon, Anne A.

N1 - Funding Information: Financial support: National Institutes of Health (grant AI 24021 to A.A.G. and grant U01 AI 069470 to P.L.); American Lebanese Syrian Associated Charities (support to St. Jude Children’s Research Hospital); National Center for Research Resources (Clinical and Translational Science Awards KL2 RR024138 and UL1 RR024139, grant K24 RR022477 [E.D.S.], and grant K23AI068280 to M.V.).

PY - 2010/6/15

Y1 - 2010/6/15

N2 - Although varicella vaccine is given to clinically stable human immunodeficiency virus (HIV)-infected children, its effectiveness is unknown. We assessed its effectiveness by reviewing the medical records of closely monitored HIV-infected children, including those receiving highly active antiretroviral therapy (HAART) between 1989 and 2007. Varicella immunization and development of varicella or herpes zoster were noted. Effectiveness was calculated by subtracting from 1 the rate ratios for the incidence rates of varicella or herpes zoster in vaccinated versus unvaccinated children. The effectiveness of the vaccine was 82% (95% confidence interval [CI], 24%-99%; P = .01) against varicella and was 100% (95% CI, 67%-100%; P<.001) against herpes zoster. When the analysis was controlled for receipt of HAART, vaccination remained highly protective against herpes zoster.

AB - Although varicella vaccine is given to clinically stable human immunodeficiency virus (HIV)-infected children, its effectiveness is unknown. We assessed its effectiveness by reviewing the medical records of closely monitored HIV-infected children, including those receiving highly active antiretroviral therapy (HAART) between 1989 and 2007. Varicella immunization and development of varicella or herpes zoster were noted. Effectiveness was calculated by subtracting from 1 the rate ratios for the incidence rates of varicella or herpes zoster in vaccinated versus unvaccinated children. The effectiveness of the vaccine was 82% (95% confidence interval [CI], 24%-99%; P = .01) against varicella and was 100% (95% CI, 67%-100%; P<.001) against herpes zoster. When the analysis was controlled for receipt of HAART, vaccination remained highly protective against herpes zoster.

UR - http://www.scopus.com/inward/record.url?scp=77952580664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952580664&partnerID=8YFLogxK

U2 - 10.1086/652798

DO - 10.1086/652798

M3 - Article

C2 - 20441519

AN - SCOPUS:77952580664

SN - 0022-1899

VL - 201

SP - 1806

EP - 1810

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 12

ER -

Effectiveness of varicella vaccine in children infected with HIV

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this